dose escalation study of 06-benzylguanine (BG) and carmustine (BCNU) Courses (each course is 3 weeks) repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 1-3 patients receive escalating doses of BG until the biochemical modulation dose l (BMDl) is determined. [clinicaltrials_resource:b6a2eaf264d4d58230bc1bb41472cf3c]

Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

Primary outcome [clinicaltrials_vocabulary:primary-outcome]

http://bio2rdf.org/clinicaltrials_resource:b6a2eaf264d4d58230bc1bb41472cf3c

Bio2RDF uri

O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors [clinicaltrials:NCT00002604]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

dose escalation study of 06-benzylguanine (BG) and carmustine (BCNU) Courses (each course is 3 weeks) repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 1-3 patients receive escalating doses of BG until the biochemical modulation dose l (BMDl) is determined. [clinicaltrials_resource:b6a2eaf264d4d58230bc1bb41472cf3c]

Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

Primary outcome [clinicaltrials_vocabulary:primary-outcome]

http://bio2rdf.org/clinicaltrials_resource:b6a2eaf264d4d58230bc1bb41472cf3c